Journal of Clinical and Experimental Ophthalmology
Open Access
ISSN: 2155-9570
+44 1223 790975
ISSN: 2155-9570
+44 1223 790975
Herbert L Gould MD FACS
New York Medical College, USA
Keynote: J Clin Exp Ophthalmol
The most common cause of blindness in the aging population is macular degeneration AMD. Currently the only management of dry AMD is dietary as a preventive measure i.e. AREDS formulation as suggested by the NIH. However using light in the infra red range, Lower Level Light Therapy (LLLT) has been shown to be effective in numerous therapeutic areas especially the eye. It has been well established that using light in the infra-red range has the effect of rehabilitating mitochondria of neural cells resulting in visual improvement in dry AMD. This method of therapy has EU approval and is now in late clinical trials in the US. PBM acts on the cellular level by activation of mitochondrial chain components and supports cell survival. The presentation will present mechanism of action and current clinical results. Eighty five to ninety percent of AMD is dry.
Herbert Gould graduated from Bowdoin College and received an MD from Columbia’s College of Physicians and Surgeons. He served his internship at the 1stMedical Division, Bellevue Hospital and was a resident at the Manhattan Eye, Ear & Throat Hospital, where, as senior resident, he initiated the Contact Lens Clinic. He continued his medical studies at the Institute of Ophthalmology (London), Harvard Medical School, and the Downstate Medical Center, NY, where he received a corneal fellowship which included Moorfields Eye Hospital, London. Gould was the founder and first president of the New York Kerato refractive Society. He has been a Teaching Fellow at State University of New York, was Assistant Clinical Professor in Ophthalmology at State University of New York (Downstate), Associate Clinical Professor at New York Medical College, and served as an Instructor at the American Academy of Ophthalmology.